2017-07-21 Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma
2017-07-03 Bayer starts Phase III study program with Vilaprisan in the treatment of symptomatic uterine fibroids
2017-04-28 Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
2017-03-06 EINSTEIN CHOICE Study with Bayer’s Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17
